Skip to main content

MUTACIONES EN EL DNA MITOCONDRIAL Y NUCLEAR ASOCIADAS A ENFERMEDADES MITOCONDRIALES: CONFIRMACION DE PATOGENICIDAD Y POSIBILIDADES TERAPEUTICAS.

PI17/00021

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2017
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION SANITARIA ARAGON
Execution centre INSTITUTO DE INVESTIGACION SANITARIA ARAGON

Resultados relacionados

Resultados totales (Incluyendo duplicados): 24
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

The decrease in mitochondrial DNA mutation load parallels visual recovery in a Leber hereditary optic neuropathy patient

  • Emperador, S.
  • Vidal, M.
  • Hernández-Ainsa, C.
  • Ruiz-Ruiz, C.
  • Woods, D.
  • Morales-Becerra, A.
  • Arruga, J.
  • Artuch, R.
  • López-Gallardo, E.
  • Bayona-Bafaluy, M.P.
  • Montoya, J.
  • Ruiz-Pesini, E.
The onset of Leber hereditary optic neuropathy is relatively rare in childhood and, interestingly, the rate of spontaneous visual recovery is very high in this group of patients. Here, we report a child harboring a rare pathological mitochondrial DNA mutation, present in heteroplasmy, associated with the disease. A patient follow-up showed a rapid recovery of the vision accompanied by a decrease of the percentage of mutated mtDNA. A retrospective study on the age of recovery of all childhood-onset Leber hereditary optic neuropathy patients reported in the literature suggested that this process was probably related with pubertal changes.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Las enfermedades raras en las patologías neurometabólicas

  • Montoya, J.
  • Arenas, J.
  • Ruiz-Pesini, E.
  • Martin-Casanueva, M.A.
Las miopatías metabólicas son un grupo de trastornos genéticos que disminuyen la capacidad del músculo esquelético para utilizar sustratos energéticos y sintetizar ATP. Estas alteraciones pueden clasificarse en tres tipos fundamentalmente: i) trastornos del metabolismo de los carbohidratos (del glucógeno y de la glucosa), ii) defectos del metabolismo lipídico, y iii) alteraciones de la fosforilación oxidativa –OXPHOS-. Las dos primeras se deben a deficiencias enzimáticas de las rutas metabólicas de degradación y síntesis de glúcidos y lípidos y muestran diversas manifestaciones clínicas, pero una buena parte de ellas cursan con intolerancia al ejercicio. Aunque un buen número de pacientes con estos trastornos musculares presentan síntomas en la infancia, el diagnóstico normalmente se retrasa hasta la segunda y tercera década de la vida. Por tanto, reconocer las características clínicas de estas deficiencias conduce a un diagnóstico precoz y a un mejor tratamiento. Las enfermedades mitocondriales son un grupo de trastornos originados por una deficiencia en la síntesis de ATP a través del sistema de fosforilación oxidativa. Este sistema está formado por proteínas codificadas en los dos genomas de la célula (nuclear y mitocondrial) y, por tanto, pueden presentar un modelo de herencia mendeliano o materno. En esta revisión se describirán las características especiales del sistema genético mitocondrial y las principales mutaciones que causan enfermedades en humanos. Metabolic myopathies are genetic disorders that decrease the capacity of skeletal muscle to use energy substrates and ATP. These disturbances can be classified into three categories: i) disorders of carbohydrate metabolism (glycogen and glucose), ii) defects in lipid metabolism, and iii) dysfunctions of oxidative phosphorylation -OXPHOS-. The first two are caused by enzyme deficiencies involved in the metabolic pathways of degradation and synthesis of carbohydrates and lipids, and although they show distinct clinical manifestations, exercise intolerance is a predominant symptom present in most of them. Although a good number of patients with these muscle disorders display symptoms in childhood, the diagnosis is often delayed until the second and third decades of life. Therefore, recognizing the clinical features of these deficiencies can lead to an earlier diagnosis and better treatment. Mitochondrial diseases are a group of disorders caused by an alteration of the oxidative phosphorylation system, that leads to a deficient synthesis of ATP. This system is composed of proteins codified in the two genetic systems of the cell, the nuclear and mitochondrial genomes, and, therefore, the mode of inheritance could be either Mendelian or maternal. This review will describe the special characteristics of the mitochondrial genetic system and the main mutations in mtDNA that cause human diseases.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Plasma coenzyme Q10 status is impaired in selected genetic conditions

  • Montero, R.
  • Yubero, D.
  • Salgado, M.C.
  • González, M.J.
  • Campistol, J.
  • O''Callaghan, M.D.M.
  • Pineda, M.
  • Delgadillo, V.
  • Maynou, J.
  • Fernandez, G.
  • Montoya, J.
  • Ruiz-Pesini, E.
  • Meavilla, S.
  • Neergheen, V.
  • García-Cazorla, A.
  • Navas, P.
  • Hargreaves, I.
  • Artuch, R.
Identifying diseases displaying chronic low plasma Coenzyme Q10 (CoQ) values may be important to prevent possible cardiovascular dysfunction. The aim of this study was to retrospectively evaluate plasma CoQ concentrations in a large cohort of pediatric and young adult patients. We evaluated plasma CoQ values in 597 individuals (age range 1 month to 43 years, average 11 years), studied during the period 2005-2016. Patients were classified into 6 different groups: control group of healthy participants, phenylketonuric patients (PKU), patients with mucopolysaccharidoses (MPS), patients with other inborn errors of metabolism (IEM), patients with neurogenetic diseases, and individuals with neurological diseases with no genetic diagnosis. Plasma total CoQ was measured by reverse-phase high-performance liquid chromatography with electrochemical detection and ultraviolet detection at 275¿nm. ANOVA with Bonferroni correction showed that plasma CoQ values were significantly lower in the PKU and MPS groups than in controls and neurological patients. The IEM group showed intermediate values that were not significantly different from those of the controls. In PKU patients, the Chi-Square test showed a significant association between having low plasma CoQ values and being classic PKU patients. The percentage of neurogenetic and other neurological patients with low CoQ values was low (below 8%). In conclusión, plasma CoQ monitoring in selected groups of patients with different IEM (especially in PKU and MPS patients, but also in IEM under protein-restricted diets) seems advisable to prevent the possibility of a chronic blood CoQ suboptimal status in such groups of patients.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Muscle Involvement in a Large Cohort of Pediatric Patients with Genetic Diagnosis of Mitochondrial Disease

  • Jou, C.
  • Ortigoza-Escobar, J.D.
  • Ocallaghan, M.M.
  • Nascimento, A.
  • Darling, A.
  • Pias-Peleteiro, L.
  • Perez-Duenas, B.
  • Pineda, M.
  • Codina, A.
  • Arjona, C.
  • Armstrong, J.
  • Palau, F.
  • Ribes, A.
  • Gort, L.
  • Tort, F.
  • Navas, P.
  • Ruiz-Pesini, E.
  • Emperador, S.
  • Lopez-Gallardo, E.
  • Bayona-Bafaluy, P.
  • Montero, R.
  • Jimenez-Mallebrera, C.
  • Garcia-Cazorla, A.
  • Montoya, J.
  • Yubero, D.
  • Artuch, R.
Mitochondrial diseases (MD) are a group of genetic and acquired disorders which present significant diagnostic challenges. Here we report the disease characteristics of a large cohort of pediatric MD patients (n = 95) with a definitive genetic diagnosis, giving special emphasis on clinical muscle involvement, biochemical and histopathological features. Of the whole cohort, 51 patients harbored mutations in nuclear DNA (nDNA) genes and 44 patients had mutations in mitochondrial DNA (mtDNA) genes. The nDNA patients were more likely to have a reduction in muscle fiber succinate dehydrogenase (SDH) stains and in SDH-positive blood vessels, while a higher frequency of mtDNA patients had ragged red (RRF) and blue fibers. The presence of positive histopathological features was associated with ophthalmoplegia, myopathic facies, weakness and exercise intolerance. In 17 patients younger than two years of age, RRF and blue fibers were observed only in one case, six cases presented cytochrome c oxidase (COX) reduction/COX-fibers, SDH reduction was observed in five and all except one presented SDH-positive blood vessels. In conclusion, muscle involvement was a frequent finding in our series of MD patients, especially in those harboring mutations in mtDNA genes.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Increasing mtDNA levels as therapy for mitochondrial optic neuropathies

  • Ruiz-Pesini, E.
  • Emperador, S.
  • López-Gallardo, E.
  • Hernández-Ainsa, C.
  • Montoya, J.
Leber hereditary optic neuropathy (LHON) is a rare, inherited mitochondrial disease. No treatment has shown a clear-cut benefit on a clinically meaningful end-point. Primary open-angle glaucoma (POAG) is a frequent, acquired optic neuropathy. Lowering intraocular pressure (IOP) reduces disease progression. However, current methods to decelerate this progression are recognized as being inadequate. Therefore, there is a clear need to look for new therapeutic approaches. The growing evidence indicates that POAG can also be a mitochondrial optic neuropathy (MON). Several risk elements are common for both diseases and all of them decrease mitochondrial (mt)DNA content. Based on these susceptibility factors and their molecular mechanism, we suggest herein pharmacological therapies targeted to increase mtDNA levels, oxidative phosphorylation (OXPHOS) capability, and mitochondrial energy production as treatments for MONs.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Food derived respiratory complex I inhibitors modify the effect of Leber hereditary optic neuropathy mutations

  • López-Gallardo, E.
  • Emperador, S.
  • Hernández-Ainsa, C.
  • Montoya, J.
  • Bayona-Bafaluy, M.P.
  • Ruiz-Pesini, E.
Mitochondrial DNA mutations in genes encoding respiratory complex I polypeptides can cause Leber hereditary optic neuropathy. Toxics affecting oxidative phosphorylation system can also cause mitochondrial optic neuropathy. Some complex I inhibitors found in edible plants might differentially interact with these pathologic mutations and modify their penetrance. To analyze this interaction, we have compared the effect of rotenone, capsaicin and rolliniastatin-1 on cybrids harboring the most frequent Leber hereditary optic neuropathy mutations and found that m.3460G > A mutation increases rotenone resistance but capsaicin and rolliniastatin-1 susceptibility. Thus, to explain the pathogenicity of mitochondrial diseases due to mitochondrial DNA mutations, their potential interactions with environment factors will have to be considered.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Mutations of the mitochondrial carrier translocase channel subunit TIM22 cause early-onset mitochondrial myopathy

  • Pacheu-Grau, David
  • Callegari, Sylvie
  • Emperador, Sonia
  • Thompson, Kyle
  • Aich, Abhishek
  • Topol, Sarah E.
  • Spencer, Emily G.
  • McFarland, Robert
  • Ruiz-Pesini, Eduardo
  • Torkamani, Ali
  • Taylor, Robert W.
  • Montoya, Julo
  • Rehling, Peter
Protein import into mitochondria is facilitated by translocases within the outer and the inner mitochondrial membranes that are dedicated to a highly specific subset of client proteins. The mitochondrial carrier translocase (TIM22 complex) inserts multispanning proteins, such as mitochondrial metabolite carriers and translocase subunits (TIM23, TIM17A/B and TIM22), into the inner mitochondrial membrane. Both types of substrates are essential for mitochondrial metabolic function and biogenesis. Here, we report on a subject, diagnosed at 1.5 years, with a neuromuscular presentation, comprising hypotonia, gastroesophageal reflux disease and persistently elevated serum and Cerebrospinal fluid lactate (CSF). Patient fibroblasts displayed reduced oxidative capacity and altered mitochondrial morphology. Using trans-mitochondrial cybrid cell lines, we excluded a candidate variant in mitochondrial DNA as causative of these effects. Whole-exome sequencing identified compound heterozygous variants in the TIM22 gene (NM_013337), resulting in premature truncation in one allele (p.Tyr25Ter) and a point mutation in a conserved residue (p.Val33Leu), within the intermembrane space region, of the TIM22 protein in the second allele. Although mRNA transcripts of TIM22 were elevated, biochemical analyses revealed lower levels of TIM22 protein and an even greater deficiency of TIM22 complex formation. In agreement with a defect in carrier translocase function, carrier protein amounts in the inner membrane were found to be reduced. This is the first report of pathogenic variants in the TIM22 pore-forming subunit of the carrier translocase affecting the biogenesis of inner mitochondrial membrane proteins critical for metabolite exchange.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Whole sequence of the mitochondrial DNA genome of Kearns Sayre Syndrome patients: Identification of deletions and variants

  • Saldaña-Martínez, A.
  • Muñoz, M.D.L.
  • Pérez-Ramírez, G.
  • Montiel-Sosa, J.F.
  • Montoya, J.
  • Emperador, S.
  • Ruiz-Pesini, E.
  • Cuevas-Covarrubias, S.
  • López-Valdez, J.
  • Ramírez, R.G.
Mitochondria both produce the energy of the cell as ATP via respiration and regulate cellular metabolism. Accordingly, any deletion or mutation in the mitochondrial DNA (mtDNA) may result in a disease. One of these diseases is Kearns Sayre syndrome (KSS), described for the first time in 1958, where different large-scale deletions of different sizes and at different positions have been reported in the mitochondrial genome of patients with similar clinical symptoms. In this study, sequences of the mitochondrial genome of three patients with clinic features of KSS were analyzed. Our results revealed the position, heteroplasmy percentage, size of deletions, and their haplogroups. Two patients contained deletions reported previously and one patient showed a new deletion not reported previously. These results display for the first time a systematic analysis of mtDNA variants in the whole mtDNA genome of patients with KSS to help to understand their association with the disease.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

NAD(P)HX dehydratase (NAXD) deficiency: a novel neurodegenerative disorder exacerbated by febrile illnesses

  • Van Bergen, N.J.
  • Guo, Y.
  • Rankin, J.
  • Paczia, N.
  • Becker-Kettern, J.
  • Kremer, L.S.
  • Pyle, A.
  • Conrotte, J.F.
  • Ellaway, C.
  • Procopis, P.
  • Prelog, K.
  • Homfray, T.
  • Baptista, J.
  • Baple, E.
  • Wakeling, M.
  • Massey, S.
  • Kay, D.P.
  • Shukla, A.
  • Girisha, K.M.
  • Lewis, L.E.S.
  • Santra, S.
  • Power, R.
  • Daubeney, P.
  • Montoya, J.
  • Ruiz-Pesini, E.
  • Kovacs-Nagy, R.
  • Pritsch, M.
  • Ahting, U.
  • Thorburn, D.R.
  • Prokisch, H.
  • Taylor, R.W.
  • Christodoulou, J.
  • Linster, C.L.
  • Ellard, S.
  • Hakonarson, H.
Physical stress, including high temperatures, may damage the central metabolic nicotinamide nucleotide cofactors [NAD(P)H], generating toxic derivatives [NAD(P)HX]. The highly conserved enzyme NAD(P)HX dehydratase (NAXD) is essential for intracellular repair of NAD(P)HX. Here we present a series of infants and children who suffered episodes of febrile illness-induced neurodegeneration or cardiac failure and early death. Whole-exome or whole-genome sequencing identified recessive NAXD variants in each case. Variants were predicted to be potentially deleterious through in silico analysis. Reverse-transcription PCR confirmed altered splicing in one case. Subject fibroblasts showed highly elevated concentrations of the damaged cofactors S-NADHX, R-NADHX and cyclic NADHX. NADHX accumulation was abrogated by lentiviral transduction of subject cells with wild-type NAXD. Subject fibroblasts and muscle biopsies showed impaired mitochondrial function, higher sensitivity to metabolic stress in media containing galactose and azide, but not glucose, and decreased mitochondrial reactive oxygen species production. Recombinant NAXD protein harbouring two missense variants leading to the amino acid changes p.(Gly63Ser) and p.(Arg608Cys) were thermolabile and showed a decrease in Vmax and increase in KM for the ATP-dependent NADHX dehydratase activity. This is the first study to identify pathogenic variants in NAXD and to link deficient NADHX repair with mitochondrial dysfunction. The results show that NAXD deficiency can be classified as a metabolite repair disorder in which accumulation of damaged metabolites likely triggers devastating effects in tissues such as the brain and the heart, eventually leading to early childhood death.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Mutations in the mitochondrial complex I assembly factor NDUFAF6 cause isolated bilateral striatal necrosis and progressive dystonia in childhood

  • Baide-Mairena, H.
  • Gaudó, P.
  • Marti-Sánchez, L.
  • Emperador, S.
  • Sánchez-Montanez, A.
  • Alonso-Luengo, O.
  • Correa, M.
  • Grau, A.M.
  • Ortigoza-Escobar, J.D.
  • Artuch, R.
  • Vázquez, E.
  • Del Toro, M.
  • Garrido-Pérez, N.
  • Ruiz-Pesini, E.
  • Montoya, J.
  • Bayona-Bafaluy, M.P.
  • Pérez-Dueñas, B.
Aim: To perform a deep phenotype characterisation in a pedigree of 3 siblings with Leigh syndrome and compound heterozygous NDUFAF6 mutations. Method: A multi-gene panel of childhood-onset basal ganglia neurodegeneration inherited conditions was analysed followed by functional studies in fibroblasts. Results: Three siblings developed gait dystonia in infancy followed by rapid progression to generalised dystonia and psychomotor regression. Brain magnetic resonance showed symmetric and bilateral cytotoxic lesions in the putamen and proliferation of the lenticular-striate arteries, latter spreading to the caudate and progressing to cavitation and volume loss. We identified a frameshift novel change (c.554_558delTTCTT; p.Tyr187AsnfsTer65) and a pathogenic missense change (c.371T>C; p.Ile124Thr) in the NDUFAF6 gene, which segregated with an autosomal recessive inheritance within the family. Patient mutations were associated with the absence of the NDUFAF6 protein and reduced activity and assembly of mature complex I in fibroblasts. By functional complementation assay, the mutant phenotype was rescued by the canonical version of the NDUFAF6. A literature review of 14 NDUFAF6 patients showed a consistent phenotype of an early childhood insidious onset neurological regression with prominent dystonia associated with basal ganglia degeneration and long survival. Interpretation: NDUFAF6-related Leigh syndrome is a relevant cause of childhood onset dystonia and isolated bilateral striatal necrosis. By genetic complementation, we could demonstrate the pathogenicity of novel genetic variants in NDUFAF6.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Molecular characterization of new FBXL4 mutations in patients with mtDNA depletion syndrome

  • Emperador, Sonia
  • Garrido-Pérez, Nuria
  • Amezcua-Gil, Javier
  • Gaudó, Paula
  • Andrés-Sanz, Julio Alberto
  • Yubero, Delia
  • Fernández-Marmiesse, Ana
  • O'Callaghan, Maria M
  • Ortigoza-Escobar, Juan D.
  • Iriondo, Marti
  • Ruiz-Pesini, Eduardo
  • García-Cazorla, Angels
  • Gil-Campos, Mercedes
  • Artuch, Rafael
  • Montoya, Julio
  • Bayona-Bafaluy, María Pilar
Encephalomyopathic mitochondrial DNA (mtDNA) depletion syndrome 13 (MTDPS13) is a rare genetic disorder caused by defects in F-box leucine-rich repeat protein 4 (FBXL4). Although FBXL4 is essential for the bioenergetic homeostasis of the cell, the precise role of the protein remains unknown. In this study, we report two cases of unrelated patients presenting in the neonatal period with hyperlactacidemia and generalized hypotonia. Severe mtDNA depletion was detected in muscle biopsy in both patients. Genetic analysis showed one patient as having in compound heterozygosis a splice site variant c.858+5G>C and a missense variant c.1510T>C (p.Cys504Arg) in FBXL4. The second patient harbored a frameshift novel variant c.851delC (p.Pro284LeufsTer7) in homozygosis. To validate the pathogenicity of these variants, molecular and biochemical analyses were performed using skin-derived fibroblasts. We observed that the mtDNA depletion was less severe in fibroblasts than in muscle. Interestingly, the cells harboring a nonsense variant in homozygosis showed normal mtDNA copy number. Both patient fibroblasts, however, demonstrated reduced mitochondrial transcript quantity leading to diminished steady state levels of respiratory complex subunits, decreased respiratory complex IV (CIV) activity, and finally, low mitochondrial ATP levels. Both patients also revealed citrate synthase deficiency. Genetic complementation assays established that the deficient phenotype was rescued by the canonical version of FBXL4, confirming the pathological nature of the variants. Further analysis of fibroblasts allowed to establish that increased mitochondrial mass, mitochondrial fragmentation, and augmented autophagy are associated with FBXL4 deficiency in cells, but are probably secondary to a primary metabolic defect affecting oxidative phosphorylation.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Oxidative phosphorylation inducers fight pathological angiogenesis

  • Bayona-Bafaluy, M.P.
  • Esteban, O.
  • Ascaso, J.
  • Montoya, J.
  • Ruiz-Pesini, E.
Pathological mutations in subunits of the oxidative phosphorylation (OXPHOS) system, or inhibitors of this biochemical pathway, increase the production of vascular endothelial growth factor (VEGF) and pathological angiogenesis. In many angiogenesis-related diseases, such as retinal, rheumatoid diseases, or cancer, OXPHOS dysfunction can be found. Thus, enhancing OXPHOS might be a promising therapeutic approach for pathologic angiogenesis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Defining the Substrate Spectrum of the TIM22 Complex Identifies Pyruvate Carrier Subunits as Unconventional Cargos

  • Gomkale, R.
  • Cruz-Zaragoza, L.D.
  • Suppanz, I.
  • Guiard, B.
  • Montoya, J.
  • Callegari, S.
  • Pacheu-Grau, D.
  • Warscheid, B.
  • Rehling, P.
In mitochondria, the carrier translocase (TIM22 complex) facilitates membrane insertion of multi-spanning proteins with internal targeting signals into the inner membrane [1–3]. Tom70, a subunit of TOM complex, represents the major receptor for these precursors [2, 4–6]. After transport across the outer membrane, the hydrophobic carriers engage with the small TIM protein complex composed of Tim9 and Tim10 for transport across the intermembrane space (IMS) toward the TIM22 complex [7–12]. Tim22 represents the pore-forming core unit of the complex [13, 14]. Only a small subset of TIM22 cargo molecules, containing four or six transmembrane spans, have been experimentally defined. Here, we used a tim22 temperature-conditional mutant to define the TIM22 substrate spectrum. Along with carrier-like cargo proteins, we identified subunits of the mitochondrial pyruvate carrier (MPC) as unconventional TIM22 cargos. MPC proteins represent substrates with atypical topology for this transport pathway. In agreement with this, a patient affected in TIM22 function displays reduced MPC levels. Our findings broaden the repertoire of carrier pathway substrates and challenge current concepts of TIM22-mediated transport processes.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Reseña (Review)

Oxidative phosphorylation dysfunction modifies the cell secretome

  • Garrido-Pérez, Nuria
  • Vela-Sebastián, Ana
  • López-Gallardo, Ester
  • Emperador, Sonia
  • Iglesias, Eldris
  • Meade, Patricia
  • Jiménez-Mallebrera, Cecilia
  • Montoya, Julio
  • Bayona-Bafaluy, M. Pilar
  • Ruiz-Pesini, Eduardo
Mitochondrial oxidative phosphorylation disorders are extremely heterogeneous conditions. Their clinical and genetic variability makes the identification of reliable and specific biomarkers very challenging. Until now, only a few studies have focused on the effect of a defective oxidative phosphorylation functioning on the cell’s secretome, although it could be a promising approach for the identification and pre-selection of potential circulating biomarkers for mitochondrial diseases. Here, we review the insights obtained from secretome studies with regard to oxidative phosphorylation dysfunction, and the biomarkers that appear, so far, to be promising to identify mitochondrial diseases. We propose two new biomarkers to be taken into account in future diagnostic trials.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Ketogenic treatment reduces the percentage of a LHON heteroplasmic mutation and increases mtDNA amount of a LHON homoplasmic mutation.

  • Emperador, Sonia
  • López-Gallardo, Ester
  • Hernández-Ainsa, Carmen
  • Habbane, Mouna
  • Montoya, Julio
  • Bayona-Bafaluy, M. Pilar
  • Ruiz-Pesini, Eduardo
Background: The vision loss in Leber hereditary optic neuropathy patients is due to mitochondrial DNA mutations. No treatment has shown a clear-cut benefit on a clinically meaningful end-point. However, clinical evidences suggest two therapeutic approaches: the reduction of the mutation load in heteroplasmic patients or the elevation of mitochondrial DNA amount in homoplasmic patients. Results: Here we show that ketogenic treatment, in cybrid cell lines, reduces the percentage of the m.13094 T > C heteroplasmic mutation and also increases the mitochondrial DNA levels of the m.11778G > A mitochondrial genotype. Conclusions: These results suggest that ketogenic diet could be a therapeutic strategy for Leber hereditary optic neuropathy.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Brain pyrimidine nucleotide synthesis and Alzheimer disease

  • Pesini, Alba
  • Iglesias, Eldris
  • Bayona-Bafaluy, M Pilar
  • Garrido-Pérez, Nuria
  • Meade, Patricia
  • Gaudó, Paula
  • Jiménez-Salvador, Irene
  • Andrés-Benito, Pol
  • Montoya, Julio
  • Ferrer, Isidro
  • Pesini, Pedro
  • Ruiz-Pesini, Eduardo
Many patients suffering late-onset Alzheimer disease show a deficit in respiratory complex IV activity. The de novo pyrimidine biosynthesis pathway connects with the mitochondrial respiratory chain upstream from respiratory complex IV. We hypothesized that these patients would have decreased pyrimidine nucleotide levels. Then, different cell processes for which these compounds are essential, such as neuronal membrane generation and maintenance and synapses production, would be compromised. Using a cell model, we show that inhibiting oxidative phosphorylation function reduces neuronal differentiation. Linking these processes to pyrimidine nucleotides, uridine treatment recovers neuronal differentiation. To unmask the importance of these pathways in Alzheimer disease, we firstly confirm the existence of the de novo pyrimidine biosynthesis pathway in adult human brain. Then, we report altered mRNA levels for genes from both de novo pyrimidine biosynthesis and pyrimidine salvage pathways in brain from patients with Alzheimer disease. Thus, uridine supplementation might be used as a therapy for those Alzheimer disease patients with low respiratory complex IV activity.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Pathological features in paediatric patients with TK2 deficiency

  • Jou, C.
  • Nascimento, A.
  • Codina, A.
  • Montoya, J.
  • López-Gallardo, E.
  • Emperador, S.
  • Ruiz-Pesini, E.
  • Montero, R.
  • Natera-de Benito, D.
  • Ortez, C. I.
  • Márquez, J.
  • Zelaya, M. V.
  • Gutiérrez-Mata, A.
  • Badosa, C.
  • Carrera-García, L.
  • Expósito-Escudero, J.
  • Roldán, M.
  • Cámara, Y.
  • Marti, R.
  • Ferrer, I.
  • Jiménez-Mallebrera, C.
  • Artuch, R.
Thymidine kinase (TK2) deficiency causes mitochondrial DNA depletion syndrome. We aimed to report the clinical, biochemical, genetic, histopathological, and ultrastructural features of a cohort of paediatric patients with TK2 deficiency. Mitochondrial DNA was isolated from muscle biopsies to assess depletions and deletions. The TK2 genes were sequenced using Sanger sequencing from genomic DNA. All muscle biopsies presented ragged red fibres (RRFs), and the prevalence was greater in younger ages, along with an increase in succinate dehydrogenase (SDH) activity and cytochrome c oxidase (COX)-negative fibres. An endomysial inflammatory infiltrate was observed in younger patients and was accompanied by an overexpression of major histocompatibility complex type I (MHC I). The immunofluorescence study for complex I and IV showed a greater number of fibres than those that were visualized by COX staining. In the ultrastructural analysis, we found three major types of mitochondrial alterations, consisting of concentrically arranged lamellar cristae, electrodense granules, and intramitochondrial vacuoles. The pathological features in the muscle showed substantial differences in the youngest patients when compared with those that had a later onset of the disease. Additional ultrastructural features are described in the muscle biopsy, such as sarcomeric de-structuration in the youngest patients with a more severe phenotype.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Síndrome de Leigh de inicio adulto, con epilepsia mioclónica progresiva, asociado a la mutación m.14487T>C: reporte de caso

  • Segura-Chávez, Darwin
  • Torres-Ramírez, Luis
  • Emperador-Ortiz, Sonia
  • Vélez-Rojas, Miriam
  • Flores-Mendoza, Martha
  • Cosentino-Esquerre, Carlos
  • Ruiz-Pesini, Eduardo
  • Montoya-Villarroya, Julio
El síndrome de Leigh o encefalomielopatía necrotizante subaguda es una enfermedad neurodegenerativa progresiva, genética y clínicamente heterogénea que se asocia por lo general con alteración del metabolismo mitocondrial a nivel de la fosforilación oxidativa. Se presenta generalmente en el periodo neonatal, pero también en la edad adulta, en la que suele expresarse con una combinación de diversas manifestaciones entre ellas parkinsonismo, alteraciones del movimiento, alteraciones neuropsiquiátricas y otras. Caso clínico Paciente masculino de 34 años de edad, que inició sus síntomas a los 18 años, algunos meses después de que su madre falleciera con síntomas parecidos, pero sin diagnóstico definido. El paciente presentó mioclonías progresivas en miembro superior derecho, espasmos palpebrales bilaterales y cervicales, asociándose posteriormente, mioclonia facial desencadenado por el habla y distonía en miembro inferior derecho que le impedía la deambulación. La resonancia magnética de encéfalo mostró la presencia de lesiones simétricas bilaterales en núcleos basales, lesiones corticales y periacueductales. El estudio genético detectó la mutación m.14487T>C en el gen ND6 del complejo 1 del sistema de fosforilación oxidativa mitocondrial en los leucocitos y células de mucosa bucal. El estudio se extendió a la abuela y dos tías maternas, asintomáticas en ese momento, quienes portaban la misma mutación. Conclusión El caso corresponde a un paciente adulto, con síndrome de Leigh, portador de la mutación m.14487T>C, la cual parece estar relacionada con un fenotipo predominantemente mioclónico progresivo, de origen cortical.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Prenatal exposure to oxidative phosphorylation xenobiotics and late-onset Parkinson disease

  • Iglesias, E.
  • Pesini, A.
  • Garrido-Pérez, N.
  • Meade, P.
  • Bayona-Bafaluy, M.P.
  • Montoya, J.
  • Ruiz-Pesini, E.
Late-onset Parkinson disease is a multifactorial and multietiological disorder, age being one of the factors implicated. Genetic and/or environmental factors, such as pesticides, can also be involved. Up to 80% of dopaminergic neurons of the substantia nigra are lost before motor features of the disorder begin to appear. In humans, these neurons are only formed a few weeks after fertilization. Therefore, prenatal exposure to pesticides or industrial chemicals during crucial steps of brain development might also alter their proliferation and differentiation. Oxidative phosphorylation is one of the metabolic pathways sensitive to environmental toxicants and it is crucial for neuronal differentiation. Many inhibitors of this biochemical pathway, frequently found as persistent organic pollutants, affect dopaminergic neurogenesis, promote the degeneration of these neurons and increase the risk of suffering late-onset Parkinson disease. Here, we discuss how an early, prenatal, exposure to these oxidative phosphorylation xenobiotics might trigger a late-onset, old age, Parkinson disease.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Down syndrome is an oxidative phosphorylation disorder

  • Bayona-Bafaluy, M.P.
  • Garrido-Pérez, N.
  • Meade, P.
  • Iglesias, E.
  • Jiménez-Salvador, I.
  • Montoya, J.
  • Martínez-Cué, C.
  • Ruiz-Pesini, E.
Down syndrome is the most common genomic disorder of intellectual disability and is caused by trisomy of chromosome 21. Several genes in this chromosome repress mitochondrial biogenesis. The goal of this study was to evaluate whether early overexpression of these genes may cause a prenatal impairment of oxidative phosphorylation negatively affecting neurogenesis. Reduction in the mitochondrial energy production and a lower mitochondrial function have been reported in diverse tissues or cell types, and also at any age, including early fetuses, suggesting that a defect in oxidative phosphorylation is an early and general event in Down syndrome individuals. Moreover, many of the medical conditions associated with Down syndrome are also frequently found in patients with oxidative phosphorylation disease. Several drugs that enhance mitochondrial biogenesis are nowadays available and some of them have been already tested in mouse models of Down syndrome restoring neurogenesis and cognitive defects. Because neurogenesis relies on a correct mitochondrial function and critical periods of brain development occur mainly in the prenatal and early neonatal stages, therapeutic approaches intended to improve oxidative phosphorylation should be provided in these periods.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Muscle involvement in a large cohort of pediatric patients with genetic diagnosis of mitochondrial disease

  • Jou, C.
  • Ortigoza-Escobar, J.D.
  • O'Callaghan, M.M.
  • Nascimento, A.
  • Darling, A.
  • Pias-Peleteiro, L.
  • Perez-Duenas, B.
  • Pineda, M.
  • Codina, A.
  • Arjona, C.
  • Armstrong, J.
  • Palau, F.
  • Ribes, A.
  • Gort, L.
  • Tort, F.
  • Navas, P.
  • Ruiz-Pesini, E.
  • Emperador, S.
  • Lopez-Gallardo, E.
  • Bayona-Bafaluy, P.
  • Montero, R.
  • Jimenez-Mallebrera, C.
  • Garcia-Cazorla, A.
  • Montoya, J.
  • Yubero, D.
  • Artuch, R.
P06.32C Mitochondrial diseases (MD) are a group of genetic and acquired disorders which present significant diagnostic challenges. Here we report the disease characteristics of a large cohort of pediatric MD patients (n = 95) with a definitive genetic diagnosis, giving special emphasis on clinical muscle involvement, biochemical and histopathological features. Of the whole cohort, 51 patients harbored mutations in nuclear DNA (nDNA) genes and 44 patients had mutations in mitochondrial DNA (mtDNA) genes. The nDNA patients were more likely to have a reduction in muscle fiber succinate dehydrogenase (SDH) stains and in SDH-positive blood vessels, while a higher frequency of mtDNA patients had ragged red (RRF) and blue fibers. The presence of positive histopathological features was associated with ophthalmoplegia, myopathic facies, weakness and exercise intolerance. In 17 patients younger than two years of age, RRF and blue fibers were observed only in one case, six cases presented cytochrome c oxidase (COX) reduction/COX-fibers, SDH reduction was observed in five and all except one presented SDH-positive blood vessels. In conclusion, muscle involvement was a frequent finding in our series of MD patients, especially in those harboring mutations in mtDNA genes.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Infectious stress triggers a POLG-related mitochondrial disease

  • Gaudo, Paula
  • Emperador, Sonia
  • Garrido-Perez, Nuria
  • Ruiz-Pesini, Eduardo
  • Yubero, Delia
  • Garcia-Cazorla, Angels
  • Artuch, Rafael
  • Montoya, Julio
  • Bayona-Bafaluy, María Pilar
A 3-year-old girl presented with severe epilepsy in the context of Borrelia infection. After ceftriaxone/lidocaine administration, she showed secondarily generalized focal crises that led to neurological and motor sequelae. Genetic studies identified in the patient two heterozygous POLG mutations (c.2591A>G; p.Asn864Ser and c.3649G>C; p.Ala1217Pro). Through analysis of POLG activity in cultured fibroblasts, we confirmed that the mutations altered the mtDNA turnover. Moreover, patient fibroblasts were more sensitive than controls in the presence of a mitochondrial replication-affecting drug, the antiretroviral azidothymidine. To test if ceftriaxone treatment could worsen the deleterious effect of the patient mutations, toxicity assays were performed. Cell toxicity, without direct effect on mitochondrial respiratory function, was detected at different antibiotic concentrations. The clinical outcome, together with the different in vitro sensitivity to ceftriaxone among patient and control cells, suggested that the mitochondrial disease symptoms were hastened by the infection and were possibly worsened by the pharmacological treatment. This study underscores the benefit of early genetic diagnosis of the patients with mitochondrial diseases, since they may be a target group of patients especially vulnerable to environmental factors.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Pathological Features in Paediatric Patients with TK2 Deficiency

  • Jou, Cristina|||0000-0002-2223-7880
  • Nascimento, Andres
  • Codina, Anna
  • Montoya, Julio|||0000-0003-1770-6299
  • López-Gallardo, Ester
  • Emperador, Sonia
  • Ruiz-Pesini, Eduardo|||0000-0002-0269-7337
  • Montero, Raquel|||0000-0003-0609-5701
  • Natera-de Benito, Daniel|||0000-0001-7764-2085
  • Ortez González, Carlos Ignacio|||0000-0001-8187-8103
  • Marquez, Jesus
  • Zelaya, Maria Victoria|||0000-0002-3692-3515
  • Gutierrez-Mata, Alfonso
  • Badosa, Carmen
  • Carrera-García, Laura|||0000-0003-4762-7591
  • Expósito-Escudero, Jesica|||0000-0002-6233-823X
  • Roldan Molina, Mònica|||0000-0002-9530-6234
  • Cámara, Yolanda|||0000-0003-2458-6942
  • Martí, Ramon A.|||0000-0002-8273-9540
  • Ferrer, Isidro|||0000-0001-9888-8754
  • Jiménez Mallebrera, Cecilia|||0000-0001-8203-7103
  • Artuch, R.|||0000-0002-3422-9685
Thymidine kinase (TK2) deficiency causes mitochondrial DNA depletion syndrome. We aimed to report the clinical, biochemical, genetic, histopathological, and ultrastructural features of a cohort of paediatric patients with TK2 deficiency. Mitochondrial DNA was isolated from muscle biopsies to assess depletions and deletions. The TK2 genes were sequenced using Sanger sequencing from genomic DNA. All muscle biopsies presented ragged red fibres (RRFs), and the prevalence was greater in younger ages, along with an increase in succinate dehydrogenase (SDH) activity and cytochrome c oxidase (COX)-negative fibres. An endomysial inflammatory infiltrate was observed in younger patients and was accompanied by an overexpression of major histocompatibility complex type I (MHC I). The immunofluorescence study for complex I and IV showed a greater number of fibres than those that were visualized by COX staining. In the ultrastructural analysis, we found three major types of mitochondrial alterations, consisting of concentrically arranged lamellar cristae, electrodense granules, and intramitochondrial vacuoles. The pathological features in the muscle showed substantial differences in the youngest patients when compared with those that had a later onset of the disease. Additional ultrastructural features are described in the muscle biopsy, such as sarcomeric de-structuration in the youngest patients with a more severe phenotype.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Multicentric Standardization of Protocols for the Diagnosis of Human Mitochondrial Respiratory Chain Defects

  • Bujan, Nuria
  • Morén, Constanza|||0000-0001-6848-7407
  • García García, Francesc Josep|||0000-0001-9021-0324
  • Blázquez, Alberto|||0000-0002-6479-3615
  • Carnicer, Clara
  • Cortés Rodríguez, Ana Belén|||0000-0003-0675-6485
  • González, Cristina
  • López-Gallardo, Ester
  • Lozano, Ester|||0000-0002-6307-9807
  • Moliner, Sonia
  • Gort, Laura|||0000-0003-4746-1034
  • Tobías, Ester|||0000-0002-9968-3651
  • Delmiro, Aitor
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Fernández-Moreno, Miguel Ángel|||0000-0002-3461-0726
  • Ruiz-Pesini, Eduardo|||0000-0002-0269-7337
  • García Arumí, Elena|||0000-0003-1848-005X
  • Rodríguez Aguilera, Juan Carlos|||0000-0002-3371-4128
  • Garrabou, Glòria|||0000-0001-8973-9933
The quantification of mitochondrial respiratory chain (MRC) enzymatic activities is essential for diagnosis of a wide range of mitochondrial diseases, ranging from inherited defects to secondary dysfunctions. MRC lesion is frequently linked to extended cell damage through the generation of proton leak or oxidative stress, threatening organ viability and patient health. However, the intrinsic challenge of a methodological setup and the high variability in measuring MRC enzymatic activities represents a major obstacle for comparative analysis amongst institutions. To improve experimental and statistical robustness, seven Spanish centers with extensive experience in mitochondrial research and diagnosis joined to standardize common protocols for spectrophotometric MRC enzymatic measurements using minimum amounts of sample. Herein, we present the detailed protocols, reference ranges, tips and troubleshooting methods for experimental and analytical setups in different sample preparations and tissues that will allow an international standardization of common protocols for the diagnosis of MRC defects. Methodological standardization is a crucial step to obtain comparable reference ranges and international standards for laboratory assays to set the path for further diagnosis and research in the field of mitochondrial diseases.